Fundamental & Clinical Pharmacology 1987-01-01

RO 13-6438 in congestive heart failure: dose-response relationship after 3 single doses.

M Komajda, P Lechat, F Elkik, Y Grosgogeat

Index: Fundam. Clin. Pharmacol. 1(6) , 459-70, (1987)

Full Text: HTML

Abstract

The dose-response for the new cardiotonic agent RO13-6438 was studied in 6 patients with grade III or IV congestive heart failure. Oral doses of 10, 20, or 30 mg of RO 13-6438 were administered on 3 consecutive days in accordance with a double-blind, randomized cross-over pattern. Hemodynamic changes, which were dose-dependent, included an increase in cardiac index combined with decreases in pulmonary capillary wedge pressure and systemic and pulmonary arterial pressures. Heart rate remained unchanged. The area under the plasma RO 13-6438 concentration time curve and the peak plasma concentration were dose-related. At each measurement, the log concentration of RO 13-6438 correlated with the percent changes in both cardiac index and capillary wedge pressure recorded at that time.

Related Compounds

  • Quazinone (Ro 13-...

Related Articles:

Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model.

2006-08-01

[J. Biomol. Screen. 11(5) , 457-68, (2006)]

Role of cGMP-inhibited phosphodiesterase and sarcoplasmic calcium in mediating the increase in basal heart rate with nitric oxide donors.

2000-10-01

[J. Mol. Cell. Cardiol. 32(10) , 1831-40, (2000)]

Relaxation of human ureteral smooth muscle in vitro by modulation of cyclic nucleotide-dependent pathways.

2000-04-01

[Urol. Res. 28(2) , 110-5, (2000)]

HL 725, an extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation in vitro.

1982-11-08

[Life Sci. 31 , 2037, (1982)]

Survival in severe left ventricular failure treated with the new nonglycosidic, nonsympathomimetic oral inotropic agents.

1987-07-01

[Chest 92(1) , 118-23, (1987)]

More Articles...